drugset / Trial / NCT00058305

Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation

NCT00058305

Phase 2 Completed 28 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of combining bryostatin 1 with vincristine in treating patients who have progressive or relapsed non-Hodgkin's lymphoma after autologous bone marrow transplantation or autologous stem cell transplantation. Drugs used in chemotherapy such as vincristine use different ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help vincristine kill more cancer cells by making the cells more sensitive to the drug

Timeline

Start
2003-03
Primary completion
2007-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vincristine Small molecule Intravenous
Subject bryostatin 1 Small molecule Intravenous